Guardant Health(GH) - 2022 Q4 - Earnings Call Presentation

Shield LDT screening commercial team • Implementing efficiencies and workforce reduction across all areas of the business • Therapy Selection on-track to be breakeven in ~12 months • $1B cash balance provides >3 year runway and will fund continued investments in MRD and Screening 16 FY 2023 guidance ▪ Total Revenue:$525 – $540 million, growth of 17$50 million ▪ Operating Expenses: below FY 2022 ▪ Free ...